Ovid Therapeutics Inc. 1OT.F Stock
Ovid Therapeutics Inc. Price Chart
Ovid Therapeutics Inc. 1OT.F Financial and Trading Overview
Ovid Therapeutics Inc. stock price | 2.98 EUR |
Previous Close | 3.48 EUR |
Open | 3.22 EUR |
Bid | 3.22 EUR x 0 |
Ask | 3.32 EUR x 0 |
Day's Range | 3.22 - 3.22 EUR |
52 Week Range | 1.41 - 3.58 EUR |
Volume | 250 EUR |
Avg. Volume | 19 EUR |
Market Cap | 227.08M EUR |
Beta (5Y Monthly) | 1.158802 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.66 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.75 EUR |
1OT.F Valuation Measures
Enterprise Value | 144.2M EUR |
Trailing P/E | N/A |
Forward P/E | -3.8795183 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1838.0679 |
Price/Book (mrq) | 1.876457 |
Enterprise Value/Revenue | 1167.188 |
Enterprise Value/EBITDA | -2.691 |
Trading Information
Ovid Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | 1.158802 |
52-Week Change | 118.42% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.58 EUR |
52 Week Low | 1.41 EUR |
50-Day Moving Average | 2.98 EUR |
200-Day Moving Average | 2.17 EUR |
1OT.F Share Statistics
Avg. Volume (3 month) | 19 EUR |
Avg. Daily Volume (10-Days) | 25 EUR |
Shares Outstanding | 70.52M |
Float | 35.85M |
Short Ratio | N/A |
% Held by Insiders | 20.86% |
% Held by Institutions | 56.40% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -43850.15% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -20.24% |
Return on Equity (ttm) | -35.96% |
Income Statement
Revenue (ttm) | 123.54K EUR |
Revenue Per Share (ttm) | 0.002 EUR |
Quarterly Revenue Growth (yoy) | -95.39% |
Gross Profit (ttm) | 1.5M EUR |
EBITDA | -53590012 EUR |
Net Income Avi to Common (ttm) | -51417184 EUR |
Diluted EPS (ttm) | -0.75 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 117.72M EUR |
Total Cash Per Share (mrq) | 1.67 EUR |
Total Debt (mrq) | 16.5M EUR |
Total Debt/Equity (mrq) | 13.64 EUR |
Current Ratio (mrq) | 17.783 |
Book Value Per Share (mrq) | 1.716 |
Cash Flow Statement
Operating Cash Flow (ttm) | -47252968 EUR |
Levered Free Cash Flow (ttm) | -29051416 EUR |
Profile of Ovid Therapeutics Inc.
Country | Germany |
State | NY |
City | New York |
Address | 41 Ninth Avenue |
ZIP | 10001 |
Phone | 646 661 7661 |
Website | https://www.ovidrx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 46 |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Q&A For Ovid Therapeutics Inc. Stock
What is a current 1OT.F stock price?
Ovid Therapeutics Inc. 1OT.F stock price today per share is 2.98 EUR.
How to purchase Ovid Therapeutics Inc. stock?
You can buy 1OT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ovid Therapeutics Inc.?
The stock symbol or ticker of Ovid Therapeutics Inc. is 1OT.F.
Which industry does the Ovid Therapeutics Inc. company belong to?
The Ovid Therapeutics Inc. industry is Biotechnology.
How many shares does Ovid Therapeutics Inc. have in circulation?
The max supply of Ovid Therapeutics Inc. shares is 70.94M.
What is Ovid Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Ovid Therapeutics Inc. PE Ratio is now.
What was Ovid Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Ovid Therapeutics Inc. EPS is -0.66 EUR over the trailing 12 months.
Which sector does the Ovid Therapeutics Inc. company belong to?
The Ovid Therapeutics Inc. sector is Healthcare.